Sheba M.J. MohanKumar

Dr. Sheba M.J. MohanKumar

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2003 in Environmental Health Perspectives
Verified
Journal Article
Open access
MAMaureen E Austin
Maureen E Austin
BKBadrinarayanan S Kasturi
Badrinarayanan S Kasturi
MBMatthew Barber
Matthew Barber
KKKurunthachalam Kannan
Kurunthachalam Kannan
PMPuliyur S MohanKumar
Puliyur S MohanKumar
SMSheba M.J. MohanKumar
Sheba M.J. MohanKumar
Environmental Health Perspectives is an Open Access journal published by the National Institute of Environmental Health Sciences. Environmental Health Perspectives is an Open Access journal published by the National Institute of Environmental Health Sciences.

1 May 2008 in NeuroToxicology
Verified
Journal Article
Closed access
SMSheba M.J. MohanKumar
Sheba M.J. MohanKumar
ACArezoo Campbell
Arezoo Campbell
MBMichelle Block
Michelle Block
BVBellina Veronesi
Bellina Veronesi

1 November 2006 in Obesity
Verified
Journal Article
Closed access
PDF file
MPMagdalena Pasarica
Magdalena Pasarica
Andrew C ShinAndrew C Shin
Andrew C Shin
MYMinghuan Yu
Minghuan Yu
HYHui‐Mei Ou Yang
Hui‐Mei Ou Yang
MRMiloni Rathod
Miloni Rathod
NDNikhil V. Dhurandhar
Nikhil V. Dhurandhar

1 June 2006 in Environmental Health Perspectives
Verified
Journal Article
Open access
MSMadhu P. Sirivelu
Madhu P. Sirivelu
SMSheba M.J. MohanKumar
Sheba M.J. MohanKumar
JWJames G. Wagner
James G. Wagner
JHJack R. Harkema
Jack R. Harkema
PMPuliyur S. MohanKumar
Puliyur S. MohanKumar
Exposure to ambient particulate matter (PM) has been linked to respiratory diseases in people living in urban communities. The mechanism by which PM produces these diseases is not clear. We hypothesized that PM could act on the brain directly to stimulate ...

1 February 2003 in Brain Research
Verified
Journal Article
Closed access
MBMatthew Barber
Matthew Barber
BKBadrinarayanan S. Kasturi
Badrinarayanan S. Kasturi
MAMaureen E. Austin
Maureen E. Austin
KPKaushik P. Patel
Kaushik P. Patel
SMSheba M.J. MohanKumar
Sheba M.J. MohanKumar
PMP.S. MohanKumar
P.S. MohanKumar

7 November 2022 in Cells
Verified
Journal Article
Open access
PDF file
MSMd Abu Bakkar Siddik
Md Abu Bakkar Siddik
CMCaitlyn Mullins
Caitlyn Mullins
AKAlyssa Kramer
Alyssa Kramer
HSHarsh Shah
Harsh Shah
RGRitchel Bueno Gannaban
Ritchel Bueno Gannaban
Andrew C ShinAndrew C Shin
Andrew C Shin
Alzheimer’s disease (AD) is an irreversible neurodegenerative disorder with a complex pathophysiology. Type 2 diabetes (T2D) is a strong risk factor for AD that shares similar abnormal features including metabolic dysregulation and brain pathology such as amyloid and/or Tau deposits. Emerging evidence suggests that circulating branched-chain amino acids (BCAAs) are associated with T2D. While excess BCAAs are shown to be harmful to neurons, its connection to AD is poorly understood. Here we show that individuals with AD have elevated circulating BCAAs and their metabolites compared to healthy individuals, and that a BCAA metabolite is correlated with the severity of dementia. APPSwe mouse model of AD also displayed higher plasma BCAAs compared to controls. In pursuit of understanding a potential causality, BCAA supplementation to HT-22 neurons was found to reduce genes critical for neuronal health while increasing phosphorylated Tau. Moreover, restricting BCAAs from diet delayed cognitive decline and lowered AD-related pathology in the cortex and hippocampus in APP/PS1 mice. BCAA restriction for two months was sufficient to correct glycemic control and increased/restored dopamine that were severely reduced in APP/PS1 controls. Treating 5xFAD mice that show early brain pathology with a BCAA-lowering compound recapitulated the beneficial effects of BCAA restriction on brain pathology and neurotransmitters including norepinephrine and serotonin. Collectively, this study reveals a positive association between circulating BCAAs and AD. Our findings suggest that BCAAs impair neuronal functions whereas BCAA-lowering alleviates AD-related pathology and cognitive decline, thus establishing a potential causal link between BCAAs and AD progression.